Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
Paige Baldwin,1,* Anders W Ohman,2,* Shifalika Tangutoori,3 Daniela M Dinulescu,2,# Srinivas Sridhar1,3,4,#1Department of Bioengineering, Northeastern University, Boston, MA, USA; 2Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 3Department o...
Main Authors: | Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-11-01
|
Series: | International Journal of Nanomedicine |
Subjects: | |
Online Access: | https://www.dovepress.com/intraperitoneal-delivery-of-nanoolaparib-for-disseminated-late-stage-c-peer-reviewed-article-IJN |
Similar Items
-
Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01) -
OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01) -
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
by: Montemorano L, et al.
Published: (2019-12-01) -
Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
by: Paige Baldwin, et al.
Published: (2019-05-01) -
Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells
by: Helena de Castro e Gloria, et al.
Published: (2021-04-01)